LENZ Therapeutics (LENZ) Non-Current Assets (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Non-Current Assets data on file, last reported at $4.2 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $4.2 million, up 22.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.1 million (up 20.17% YoY), and the FY2025 annual result was $4.5 million, up 31.8% from the prior year.
• Non-Current Assets slipped to $4.2 million in Q1 2026 per LENZ's latest filing, from $4.5 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $46.5 million in Q4 2022 and troughed at $648000.0 in Q1 2024.
• A 5-year average of $16.5 million and a median of $4.2 million in 2026 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 1053.02% in 2022, then slumped 98.37% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $46.5 million in 2022, then tumbled by 93.27% to $3.1 million in 2023, then rose by 8.14% to $3.4 million in 2024, then soared by 31.8% to $4.5 million in 2025, then fell by 6.63% to $4.2 million in 2026.
• Business Quant data shows LENZ's Non-Current Assets at $4.2 million in Q1 2026, $4.5 million in Q4 2025, and $3.7 million in Q3 2025.